Candel Therapeutics Inc
CADL
NASDAQ
Biotechnology
$11.72
USD
-0.08 (-0.68%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $864.59M
Volume 2.1M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-88.53M
TTM
-299.9%
YoY
Operating Cash Flow
$-56.02M
TTM
-87.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.2 | 4.7 | 4.7 | 6.4 | 6.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 11.2 | 13.2 | 15.8 | 16.3 | 26.7 |
Operating Income | -11.2 | -13.2 | -15.8 | -16.3 | -26.7 |
EBITDA | -10.9 | -13.0 | -15.6 | -16.1 | -26.6 |
Other Income / Expense | 5.7 | 1.1 | -13.5 | 7.7 | -12.3 |
Total Other Income / Expense | 6.4 | 1.9 | -13.7 | 7.4 | -12.2 |
Income Before Income Taxes | -4.8 | -11.3 | -29.5 | -8.9 | -38.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -4.8 | -11.3 | -29.5 | -8.9 | -38.9 |
Consolidated Net Income / Loss | -4.8 | -11.3 | -29.5 | -8.9 | -38.9 |
Net Income Attributable to Common Shareholders | -4.8 | -11.3 | -29.5 | -8.9 | -38.9 |
Basic EPS | -$0.09 | -$0.21 | -$0.54 | -$0.14 | -$0.52 |
Diluted EPS | -$0.09 | -$0.21 | -$0.58 | -$0.14 | -$0.52 |
Basic Shares Outstanding | 51.5M | 54.9M | 55.0M | 62.4M | 74.1M |
Diluted Shares Outstanding | 51.5M | 54.9M | 50.7M | 62.4M | 74.1M |